CARCINOSTATIC AGENT

PURPOSE:To obtain a carcinostatic agent for treating laryngeal carcinoma by using bleomycin in combination with IFN-alpha. CONSTITUTION:A carcinostatic agent for the treatment of laryngeal carcinoma with bleomycin is produced by using interferon-alpha for improving the activity of the bleomycin as a main component. The IFN-alpha is a glycoprotein having a molecular weight of 15,000-24,000 and containing 165-166 amino acid units. It can be produced either by the cultivation (of leukocyte, lymphoblast, etc.) or by a genetic engineering method provided that the IFN is originated from human being. Bleomycin is a tumoricidal antibiotic separated from the cultured solution of an actinomycete (Streptomyces verticillus B 80-72) and is used in a form of hydrochloride, sulfate or the like. The IFN-alpha and the bleomycin are administered in combination at an amount of preferably 10 -10 IU/kg/dose and 0.01-50mg/kg/dose, respectively, by intravenous injection, hypodermic injection, intramuscular injection or the like.